Skip to main content
OpenTrials
Completed

NCT Number: NCT00845520

Safety and Effectiveness of the Calhoun Vision Light Adjustable Intraocular Lens (LAL)

The primary objective of this study is to evaluate, for the visual correction of aphakia, the safety and effectiveness of the Calhoun Vision Light Adjustable intraocular lens (LAL) and Light Delivery Device (LDD) in treating postoperative residual refractive error by providing a stable, targeted refractive adjustment of the LAL power and lock-in treatments with the LDD.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CODET Vision Institute, Tijuana, Zona Rio, Mexico

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pre-operative regular corneal astigmatism less than or equal to 1.00 diopters by keratometry.
  • Adults between the ages of 40 and 80 inclusive.
  • Cataract causing reduction in best spectacle-corrected visual acuity to a level of 20/32 or worse.
  • Best corrected visual acuity projected (by clinical estimate based upon past ocular history and retinal exam) to be 20/25 or better after cataract removal and IOL implantation.
  • Clear intraocular media other than cataract.
  • Potentially good vision in the fellow eye with BCVA 20/40 or better.
  • Willing and able to comply with the schedule for power adjustment/lock-in treatments and the schedule for follow-up visits.
  • Fully dilated pupil diameter of more than or equal to 7.0 mm.

Exclusion criteria

  • Zonular laxity or dehiscence.
  • Pseudoexfoliation.
  • Age related macular degeneration involving the presence of geographic atrophy or soft drusen.
  • Retinal degenerative disorder that is expected to cause future vision loss.
  • Diabetes with any evidence of retinopathy.
  • Evidence of glaucomatous optic neuropathy.
  • History of uveitis.
  • Significant anterior segment pathology, such as rubeosis iridis, aniridia, or iris coloboma.
  • Corneal pathology that is either progressive or sufficient to reduce BCVA to 20/25 or worse.
  • Keratoconus or suspected of having keratoconus.
  • Corneal dystrophy including basement membrane dystrophy.
  • Previous corneal or intraocular surgery
  • Systemic medication that may increase sensitivity to UV light such as tetracycline, doxycycline, psoralens, amiodarone, and phenothiazines.
  • Complications during cataract surgery including posterior capsule rupture, zonular rupture, radial capsulorhexis tear, vitreous loss, iris trauma, corneal complications or any intraoperative abnormality that may affect the postoperative pupillary dilation, or the centration or tilt of the intraocular lens.

Treatment and study plan

Lens implantation +1.00 D postop target

Device

Lens implantation +1.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.

Other names: Light Delivery Device

Lens implantation -1.00 D postop target

Device

Lens implantation -1.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.

Other names: Light Delivery Device

Lens implantation 0.00 D postop target

Device

Lens implantation 0.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.

Other names: Light Delivery Device

Primary outcomes

  1. Percentage of Eyes Achieving a Manifest Refraction Spherical Equivalent (MRSE) Within ± 0.50 D of the Intended Adjustment Target

    Time frame: 6 months post-operative

    Predictability of post-operative refractive adjustments of the implanted LAL, with 75% of the eyes achieving a manifest refraction spherical equivalent (MRSE) within ± 0.50 D of the intended adjustment target at the point of stability. All three arms of the study had the same end point so the results were presented as one combined cohort.

Secondary outcomes

  1. Percentage of Participants With Eyes With Improvement in Uncorrected Visual Acuity (UCVA)

    Time frame: 6 months post operative

    Improvement in uncorrected visual acuity (UCVA): For those best case eyes with a pre-light treatment UCVA of 20/50 or worse, 65% of eyes should have an uncorrected visual acuity of 20/40 or better at the refractive stable point after the adjustment and lock-in treatments. All three arms of the study had the same end point so the results were presented as one combined cohort.

Other outcomes

  1. Percentage of Eyes With Best Corrected Visual Acuity (BSCVA) of 20/40 or Better

    Time frame: 12 months

    Best Corrected Visual Acuity (BSCVA): The percentage of eyes achieving overall and best case BSCVA of 20/40 or better should be comparable to the FDA grid of historical controls for intraocular lenses. All three arms of the study had the same end point so the results were presented as one combined cohort.

Sponsors and collaborators

Lead sponsor

Calhoun Vision, Inc.

Industry

Registry information

Official study title

A Prospective Multi-center Clinical Study to Evaluate the Safety and Effectiveness of the Light Adjustable Lens (LAL) in Subjects Undergoing Cataract Extraction

Important dates

Study start
2009
Primary completion
2013
Study completion
2013
First posted
Feb 18, 2009
Registry last updated
Jul 6, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.